Wednesday, February 15, 2023, San Francisco, California, 7:15 PM – 8:45 PM Pacific Time (10:15 PM – 11:45 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Renal Cell Carcinoma

Part 1 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Genitourinary Cancers Symposium

Location
San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Educational Dinner Meeting

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.  
 
Faculty
Prof Laurence Albiges, MD, PhD
Medical Oncologist
Chair, Medical Oncology Department
Gustave Roussy Cancer Center
Villejuif, France

Toni K Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Department of Medical Oncology
Dana-Farber Cancer Institute
The Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts


Thomas Powles, MBBS, MRCP, MD
Professor of Genitourinary Oncology
Barts Cancer Institute
Director of Barts Cancer Centre
Queen Mary University of London
London, United Kingdom

Moderator
Brian Rini, MD
Professor of Medicine
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee


This activity is supported by educational grants from Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck.
Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration
7:15 PM – 8:45 PM — Educational Dinner Meeting

MODULE 1: Available Data with and Ongoing Investigation of Immune Checkpoint Inhibitors in Nonmetastatic Renal Cell Carcinoma (RCC)

  • Historical data with tyrosine kinase inhibitors (TKIs) as adjuvant therapy for high-risk RCC
  • Biologic rationale for the assessment of immune checkpoint inhibitors as adjuvant therapy for RCC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase III KEYNOTE-564 trial of pembrolizumab versus placebo as adjuvant treatment for patients with clear cell RCC at increased risk of recurrence following nephrectomy
  • Published efficacy and safety findings from KEYNOTE-564 showing a disease-free survival advantage with adjuvant pembrolizumab
  • FDA approval of and identification of patients for treatment with adjuvant pembrolizumab
  • Primary data from the Phase III IMmotion010 and CheckMate 914 studies demonstrating a lack of benefit with atezolizumab monotherapy and nivolumab/ipilimumab, respectively, versus placebo as adjuvant therapy for localized RCC; implications for clinical practice
  • Ongoing Phase III studies (eg, PROSPER RCC, RAMPART trials) evaluating immune checkpoint inhibition as neoadjuvant and/or adjuvant therapy for patients with high-risk RCC

MODULE 2: Evidence-Based Selection of First-Line Therapy for Metastatic RCC (mRCC)

  • Key clinical and biologic factors guiding the selection of first-line therapy for patients with newly diagnosed metastatic RCC
  • Published efficacy and safety findings with nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC
  • Long-term follow-up data from the Phase III CheckMate 9ER trial confirming the efficacy of nivolumab in combination with cabozantinib for previously untreated advanced RCC
  • Updated efficacy and safety data from the Phase III KEYNOTE-581/CLEAR trial supporting the FDA approval of lenvatinib/pembrolizumab as first-line therapy for advanced RCC; current role in clinical practice
  • Incidence and severity of toxicities associated with various approved combination strategies for advanced treatment-naïve RCC; monitoring, including cardiovascular surveillance, and management of toxicities
  • Design of, eligibility criteria for and major efficacy and safety outcomes from the pivotal Phase III COSMIC-313 trial evaluating nivolumab/ipilimumab/cabozantinib versus nivolumab/ipilimumab for patients with previously untreated, intermediate- or poor-risk advanced RCC; potential implications for clinical practice

MODULE 3: Treatment Options for Relapsed/Refractory RCC

  • Logical sequencing of available therapies for metastatic RCC that has progressed on front-line immunotherapy and/or a TKI; factors affecting decision-making in this setting
  • Published data with and optimal incorporation of VEGF TKI-based strategies (eg, cabozantinib, lenvatinib/everolimus, axitinib) into the care of patients with progressive metastatic RCC
  • Design, entry criteria and major clinical outcomes, including overall survival, from the Phase III TIVO-3 trial comparing tivozanib to sorafenib as third- or fourth-line therapy for RCC
  • FDA approval and optimal incorporation of tivozanib into current management algorithms for patients with relapsed/refractory RCC
  • Role of rechallenge with alternative checkpoint inhibitor-based approaches for disease that has previously progressed on immunotherapy; ongoing studies (eg, TiNivo-2) attempting to evaluate this strategy
  • Available data from cohort 1 of the Phase II LITESPARK-003 study assessing belzutifan/cabozantinib as first-line treatment for advanced RCC; ongoing investigation of belzutifan alone or in combination with other systemic therapies
  • Other promising novel agents and strategies (eg, durvalumab/tremelimumab, savolitinib) under investigation for RCC

MODULE 4: Management of RCC Among Special Patient Populations

  • Incidence and optimal approaches to the management of non-clear cell RCC (eg, papillary, chromophobe)
  • Clinical trial findings (eg, SWOG S1500/PAPMET) documenting the efficacy and safety of available and investigational MET inhibitors for papillary RCC
  • Design, eligibility criteria and published results from the Phase II KEYNOTE-B61 trial evaluating pembrolizumab/lenvatinib as first-line treatment for non-clear cell RCC; implications, if any, for ongoing research and current patient care
  • Proportion of patients with von Hippel-Lindau (VHL)-associated RCC; mechanism of action of belzutifan
  • Key findings from the pivotal Phase II study MK-6482-004 assessing belzutifan for VHL-associated RCC
  • FDA approval of belzutifan for cancers associated with VHL disease and optimal integration of this agent into clinical practice
  • Spectrum, frequency and management of toxicities associated with belzutifan
  • Other novel agents and strategies under clinical development for non-clear cell RCC

Target Audience
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate recent data with and consider the current role of adjuvant anti-PD-1/PD-L1 antibody therapy for patients with RCC at high risk for recurrence after nephrectomy.
  • Consider evidence-based research findings and other clinical and biologic factors in the best-practice selection of first-line therapy for patients with metastatic RCC (mRCC).
  • Appraise available clinical trial data evaluating anti-PD-1/PD-L1 antibody/multikinase inhibitor combinations for previously untreated mRCC, and counsel patients regarding the risks and benefits of these novel regimens.
  • Review the biologic rationale for the investigation of anti-PD-1/anti-CTLA-4/multikinase inhibitor combination therapy as first-line treatment for mRCC, and appreciate available research documenting the effectiveness of this approach.
  • Develop a logical approach to the sequencing of systemic therapies for patients with advanced RCC that has progressed on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapeutic strategies.
  • Appreciate published clinical research evaluating available and investigational agents for non-clear cell RCC, and consider the applicability of these strategies in current clinical care.
  • Recognize the side effects and toxicities commonly associated with approved and investigational therapies, and develop supportive care plans for patients with RCC undergoing treatment.
  • Recall available and emerging data with other novel and investigational agents currently being studied for RCC, and, where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYProf Albiges and Dr Choueiri have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr PowlesConsulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme LLC, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc; Travel/Accommodation/Expenses: AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Merck Sharp & Dohme LLC, Pfizer Inc, Roche Laboratories Inc; Nonrelevant Financial Relationship: Mashup Media LLC.

MODERATORBrian Rini, MD Advisory Committee and Consulting Agreements: Alkermes, Allogene Therapeutics, Aravive Inc, Arrowhead Pharmaceuticals, Athenex, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Debiopharm, Eisai Inc, EUSA Pharma, Genentech, a member of the Roche Group, Merck, NiKang Therapeutics Inc, Pfizer Inc, Sanofi, Shionogi Inc, Surface Oncology; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, F Hoffmann-La Roche Ltd, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Surface Oncology; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Stock Options/Ownership — Public Company: PTC Therapeutics; Nonrelevant Financial Relationship: MashUpMD—Podcast partnership.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MDDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Aveo Pharmaceuticals, Eisai Inc, Exelixis Inc, and Merck.

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room
Yerba Buena – Salon 7 (Lower B2 Level)

Directions
The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center, where the 2023 ASCO Genitourinary Cancers Symposium is taking place.

 
This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of renal cell carcinoma.

There is no fee to participate in this hybrid event. For the in-person symposium in San Francisco, preregistration is required as seating is limited.

​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.